دورية أكاديمية
Reducing the Initial Number of Rituximab Maintenance-Therapy Infusions for ANCA-associated Vasculitides: Randomized-Trial Post-Hoc Analysis
| العنوان: | Reducing the Initial Number of Rituximab Maintenance-Therapy Infusions for ANCA-associated Vasculitides: Randomized-Trial Post-Hoc Analysis |
|---|---|
| المؤلفون: | Charles, Pierre, Dechartres, Agnès, Terrier, Benjamin, Cohen, Pascal, Faguer, Stanislas, Huart, Antoine, Hamidou, Mohamed, Agard, Christian, Bonnotte, Bernard, Samson, Maxime, Karras, Alexandre, Jourde-Chiche, Noémie, Lifermann, François, Gobert, Pierre, Hanrotel-Saliou, Catherine, Godmer, Pascal, Martin-Silva, Nicolas, Pugnet, Grégory, Matignon, Marie, Aumaitre, Olivier, Viallard, Jean-François, Maurier, François, Meaux-Ruault, Nadine, Riviere, Sophie, Sibilia, Jean, Puechal, Xavier, Mouthon, Luc, Guillevin, Loïc |
| المساهمون: | Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Mutualiste de Montsouris (IMM), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département de Néphrologie et Transplantation d'organes CHU Toulouse, Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Centre Hospitalier de Dax, Service de Néphrologie, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital de la Cavale Blanche - CHRU Brest (CHU - BREST ), Centre hospitalier Bretagne Atlantique (Morbihan) (CHBA), Service de médecine interne CHU Caen, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand, Hôpitaux Privés de Metz (HPMetz), Service de médecine interne (Med Int - BESANCON), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire Montpellier (CHRU Montpellier) |
| المصدر: | Rheumatology ; https://hal.sorbonne-universite.fr/hal-03894246Test ; Rheumatology, 2020, 59 (10), pp.2970--2975. ⟨10.1093/rheumatology/kez621⟩ |
| بيانات النشر: | HAL CCSD |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | [SDV]Life Sciences [q-bio] |
| الوصف: | International audience ; Abstract Objective The randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter's titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12. Methods MAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free survival rates in each arm as primary end points. Exploratory subgroup analyses were run according to CYC or rituximab induction and newly diagnosed or relapsing AAV. Results At M3, M6, M9 and M12, respectively, among the 161 patients included, 79/80 (98.8%), 76/80 (95%), 74/80 (92.5%) and 73/80 (91.3%) from D0, and 80/81 (98.8%), 78/81 (96.3%), 76/81 (93.8%) and 76/81 (93.8%) from D0+D14 groups were alive and relapse-free. No between-group differences were observed. Results were not affected by CYC or rituximab induction, or newly diagnosed or relapsing AAV. Conclusions We were not able to detect a difference between the relapse-free survival rates for up to M12 for the D0 and D0+D14 rituximab-infusion groups, which could suggest that omitting the D14 rituximab remission-maintenance dose did not modify the short-term relapse-free rate. Nevertheless, results at M12 may also have been influenced by the rituximab-infusion strategies for both groups. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/32150263; hal-03894246; https://hal.sorbonne-universite.fr/hal-03894246Test; https://hal.sorbonne-universite.fr/hal-03894246/documentTest; https://hal.sorbonne-universite.fr/hal-03894246/file/378.pdfTest; PUBMED: 32150263 |
| DOI: | 10.1093/rheumatology/kez621 |
| الإتاحة: | https://doi.org/10.1093/rheumatology/kez621Test https://hal.sorbonne-universite.fr/hal-03894246Test https://hal.sorbonne-universite.fr/hal-03894246/documentTest https://hal.sorbonne-universite.fr/hal-03894246/file/378.pdfTest |
| حقوق: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.A6DDCE9F |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/rheumatology/kez621 |
|---|